Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.26% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CTKB · Mar 31, 2024
Cytek Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-24-021723General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
8.82% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
20.96% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
122.03% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
51.30% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-23.93% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
21.84% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
12.57% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History21 statesSelf-history eligible
Sep 30, 20210/7 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/8 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20235/8 normalizedLevel 3Sep 30, 20237/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 2.41%
- Current
- 1.26%
- Delta
- -1.14%
- Previous
- 2.74%
- Current
- 8.82%
- Delta
- 6.08%
- Previous
- 17.67%
- Current
- 20.96%
- Delta
- 3.29%
- Previous
- 31.54%
- Current
- 122.03%
- Delta
- 90.49%
- Previous
- 56.69%
- Current
- 51.30%
- Delta
- -5.39%
- Previous
- -14.43%
- Current
- -23.93%
- Delta
- -9.50%
- Previous
- 22.87%
- Current
- 21.84%
- Delta
- -1.04%
- Previous
- 11.42%
- Current
- 12.57%
- Delta
- 1.15%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CTKB Fundamental State →Transitioned To · CTKB Fundamental State →Transitioned To · CTKB CAPEX_INTENSITY_DECREASED →Transitioned To · CTKB CASH_GENERATION_INCREASED →Transitioned To · CTKB GROWTH_INCREASED →Transitioned To · CTKB INVENTORY_PRESSURE_INCREASED →Transitioned To · CTKB MARGIN_DECREASED →Transitioned To · CTKB PROFITABILITY_DECREASED →Transitioned To · CTKB R_AND_D_INTENSITY_DECREASED →Transitioned To · CTKB SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.